BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Medtronic
UBS
Farmers Insurance
Chubb
Teva
QuintilesIMS
Merck
Deloitte

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022108

« Back to Dashboard

NDA 022108 describes APLENZIN, which is a drug marketed by Valeant Pharms North and is included in one NDA. It is available from two suppliers. There are eight patents protecting this drug and three Paragraph IV challenges. Additional details are available on the APLENZIN profile page.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bupropion hydrobromide profile page.
Summary for 022108
Tradename:APLENZIN
Applicant:Valeant Pharms North
Ingredient:bupropion hydrobromide
Patents:8
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022108
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108 NDA Valeant Pharmaceuticals North America LLC 0187-5810 0187-5810-07 7 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5810-07)
APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108 NDA Valeant Pharmaceuticals North America LLC 0187-5810 0187-5810-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (0187-5810-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength174MG
Approval Date:Apr 23, 2008TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Jun 27, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Jun 27, 2026Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS
Patent:➤ SubscribePatent Expiration:Jun 27, 2026Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Fish and Richardson
Dow
QuintilesIMS
Cantor Fitzgerald
Novartis
McKinsey
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot